First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.
Bottom Line: Four main explanations for this heterogeneity have been proposed: differences in the extent and timing of 'crossover' to taxanes in the control groups; differences in the types of patient included; differences in the effectiveness of the research regimens used; differences in the effectiveness of the control regimens used.Heterogeneity 'within' and 'between' groups was formally compared using the F-ratio.Further investigation of this question would be useful.
Affiliation: Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK.Show MeSH
Related in: MedlinePlus
Mentions: The pooled results of all of these trials suggested a benefit to combination regimens (AOCTG, 1998). However, it is useful to examine that analysis in more detail, separating the trials into those which used platinum at the same dose in both the single agent and combination arms and those that increased the dose in the single agent arm. A summary of these trials split in this way is given in Table 5Table 5Trials comparing single agent platinum vs platinum in combination and the meta-anaylsis plots are given in Figure 3Figure 3
Affiliation: Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK.